Our Company was founded in 1998 on the belief that autologous point of care therapies are the preferred standard of care for both patient and physician. We are committed to developing, delivering and supporting the highest quality equipment, procedures, protocols and educational training available. SafeBlood® Technologies primary goal is to provide physicians and facilities with the ability to provide the SafeBlood Graft™ procedure, an autologous tissue graft having a wide range of possibilities.

SafeBlood® Technologies has developed a unique program that features a multi-disciplined approach for the treatment of both acute and chronic wounds. Our protocols begin with inclusion criteria and eligibility documentation followed by wound specific proprietary ratios of activators for the stabilization and application of the graft matrix. SOP's are in place for care/treatment cycles that include appropriate dressing and therapy based on wound etiology. Documentation templates are supplied to track and automatically chart a wound's progress. Physician consultants are available to discuss and instruct in proper grafting technique. Reimbursement consultants will assist and address coding concerns. Marketing support is included with all SafeBlood® Technologies certified programs. This includes, but is not limited to, market analysis, various wound care proformas, brochure templates, marketing support as well as science information/data/research to support your program.

SafeBlood® Technologies understands there are other vendors and perfusion groups that offer similar treatment modalities. However, we know of none that provide the depth of knowledge, experience, history and support in such a total and comprehensive approach.

We hope the following information will be of benefit to medical professionals and patients alike. If you would like additional information please call 1-800-854-4855. Thank you again for your time and interest.

Sincerely, Jim Limbird, President SafeBlood® Technologies Inc.